Last reviewed · How we verify
Statin Medication Management
Statin Medication Management is a Small molecule drug developed by Syntrillo, Inc. It is currently in Phase 1 development.
Statin medications are used to manage conditions such as Peripheral Artery Disease, Peripheral Vascular Disease, Peripheral Arterial Disease, Type 2 Diabetes, and Diabetes Mellitus. The exact mechanism of statin medications is unknown, but they are often used in conjunction with other interventions like Ezetimibe and Niaspan.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Statin Medication Management |
|---|---|
| Sponsor | Syntrillo, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Acute Kidney Injury
- Septic shock
- Cellulitis
- Stroke
- Hyponatremia
- Hyperkalemia
- Hypotension
- Syncope
- Fluid overload
- Upper Respiratory Tract Infection
- Accidental Overdose
- Urinary tract infection
Key clinical trials
- Preoperative Statin Use and Major Adverse Cardiovascular Events in Liver Transplant Recipients
- Optimizing Non-statin Agents for ASCVD
- PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis (PHASE3)
- Statin Intervention for Severe Early-Onset Placental Insufficiency. (STATIN-PRE Trial) (PHASE2)
- Community-based, eHealth Supported Type 2 Diabetes Care by Lay Village Health Workers in Rural Lesotho (NA)
- DNV001 Injection in Patients With Hypercholesterolemia (PHASE2)
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (NA)
- Phone-based Intervention Under Nurse Guidance After Stroke 2 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Statin Medication Management CI brief — competitive landscape report
- Statin Medication Management updates RSS · CI watch RSS
- Syntrillo, Inc portfolio CI
Frequently asked questions about Statin Medication Management
What is Statin Medication Management?
Who makes Statin Medication Management?
What development phase is Statin Medication Management in?
What are the side effects of Statin Medication Management?
Related
- Manufacturer: Syntrillo, Inc — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing